end. Around Europe, London's FTSE 100 index finished 0.1 percent higher, while Paris's CAC 40 added 0.3 percent and Frankfurt's DAX inched 0.03 percent higher. But the Swiss Market Index fell 0.5 percent in Zurich. A slight rise in oil prices helped support the European energy sector, with BP up 1.5 percent. Total gained 1.8 percent, also buoyed by bullish comments from Credit Suisse First Boston, which said the French group's upstream growth visibility was one of the strongest within the sector. On the downside, Roche shed 2 percent after its Japanese unit Chugai told the government that two teenage boys exhibited abnormal behaviour that led to their deaths after taking Roche's anti-flu drug Tamiflu. GlaxoSmithKline was another pharmaceutical decliner, off 1.2 percent after data showed that a new treatment for hepatitis B developed by U.S. drugmaker Idenix Pharmaceuticals and Switzerland's Novartis worked better than the current standard drug, lamivudine. Lamivudine is sold as Epivir-HBV by GlaxoSmithKline. In New York, markets were little changed, with the Dow Jones industrial average down 0.03 percent and the technology-laced Nasdaq Composite off 0.1 percent.
